Who Is Actually Running These Studies
The research ecosystem is broader than many people assume. The National Institutes of Health funds a large share of asthma research through the National Heart, Lung, and Blood Institute, but pharmaceutical companies sponsor many of the late-stage trials that lead to FDA approvals. Academic medical centers form a third pillar, often partnering with both federal agencies and industry sponsors.
The American Lung Association operates a network of Airways Clinical Research Centers (ACRC) at major institutions across the country. These centers are currently running the TRIM study, which is testing whether roflumilast can help adults with poorly controlled asthma and elevated body mass index. The study sites stretch from the University of Arizona in Tucson to Northwestern in Chicago, Mount Sinai in New York, Duke in North Carolina, and the Vermont Lung Center. Each site has a dedicated research coordinator who handles screening and enrollment.
Eli Lilly is sponsoring the RENEW-Asthma trial, evaluating an investigational drug called brenipatide for adults with moderate-to-severe asthma. The study runs for approximately 65 weeks including screening, treatment, and follow-up. Meanwhile, Generate Biomedicines is enrolling patients for SOLAIRIA-2, a study of GB-0895 as an add-on therapy for adolescents and adults whose severe asthma is not controlled by inhaled corticosteroids and standard controllers.
In the biologic space, the PASSAGE study generated real-world evidence on tezepelumab across diverse patient populations, including groups often underrepresented in research: Black and African American patients, adolescents, people with a history of smoking, and those with coexisting mild-to-moderate COPD. This matters because the effectiveness of a treatment seen in a narrowly selected trial population does not always translate to the broader mix of patients seen in everyday practice.
At the University of Virginia, a screening protocol is enrolling adults aged 18 to 65 with mild allergic asthma for studies that include allergy testing, breathing tests, and blood work. The screening itself provides compensation, and participants who qualify may be invited into future treatment studies.
What Joining a Trial Actually Involves
Clinical trials are structured in phases, and understanding the phase helps set expectations. Phase I studies focus on safety and dosing in a small group. Phase II expands the group to look at effectiveness and side effects. Phase III trials involve larger populations and compare the new treatment against a placebo or existing standard. Phase IV happens after approval, collecting real-world data on long-term safety and effectiveness.
Most asthma trials that are recruiting patients fall into the Phase II to Phase IV range. The commitment varies. Some studies require visits every few weeks over a year or more. Others are shorter. Blood draws, lung function tests, and questionnaires are common. A few trials involve bronchoscopy or induced sputum samples, but many do not.
A question that comes up in nearly every conversation about trial participation is cost. Study-related treatments, tests, and doctor visits are provided to participants at no charge. Many trials also offer compensation for time and travel, though the amounts vary by study length and complexity. Screening visits sometimes carry their own payment. For example, the UVA screening protocol mentioned above offers compensation for completing the screening process.
Transportation and scheduling can be real barriers. Some research sites are located in urban academic centers that may require hours of travel for participants who live in rural areas. A few studies offer travel reimbursement or arrange transportation, but this is not universal. Asking about practical support during the screening call is entirely appropriate.
Comparison of Active Asthma Clinical Trial Types
| Trial Type | Example Study | Who It Is For | Typical Duration | Key Consideration |
|---|
| Inhaled Triple Therapy | Breztri KALOS/LOGOS | Moderate-to-severe asthma, 12+ years | 24-52 weeks | Now FDA-approved; post-approval studies ongoing |
| Oral Anti-inflammatory | TRIM (Roflumilast) | Poorly controlled asthma, elevated BMI, 18+ years | Varies by site | Five ACRC locations across the US |
| Novel Biologic | RENEW-Asthma (Brenipatide) | Moderate-to-severe uncontrolled asthma, adults | ~65 weeks | Eli Lilly-sponsored; multiple dose levels tested |
| Anti-TSLP Biologic | PASSAGE (Tezepelumab) | Severe uncontrolled asthma, 12+ years, diverse populations | 52 weeks | Phase IV real-world evidence; completed enrollment |
| Investigational Biologic | SOLAIRIA-2 (GB-0895) | Severe uncontrolled asthma, adolescents and adults | 52 weeks | Add-on to ICS and standard controllers |
| Screening Protocol | UVA Asthma Screening | Mild allergic asthma, 18-65 years | Up to 3 visits | Pathway to future studies; compensation provided |
Finding a Trial That Fits
ClinicalTrials.gov remains the central registry for studies across the country. As of early August, the database lists thousands of asthma-related studies at various stages. The challenge is filtering through them. Searching by location, trial phase, and recruitment status narrows the list considerably. Many trials listed as "recruiting" are actively seeking participants; others may be "not yet recruiting" or "completed."
The American Lung Association's clinical trial finder offers a more curated experience, focusing on studies conducted through its ACRC network. The advantage here is that these centers are established research sites with experienced staff and standardized protocols.
Regional research hubs are worth knowing about. The University of Arizona Asthma and Airway Disease Research Center in Tucson runs multiple studies and has a dedicated research coordinator handling inquiries. Northwestern's Airways Disease Center in Chicago is similarly active. Duke, Mount Sinai, and National Jewish Health in Denver round out a geography that, while not universal, covers much of the country.
For patients considering a biologic trial, eligibility often hinges on blood eosinophil counts, exacerbation history, and current medication use. The criteria are specific because the therapies target specific inflammatory pathways. Someone with low eosinophils might qualify for a tezepelumab study but not for an anti-IL-5 trial. Understanding these distinctions can help narrow the search before making calls.
Questions Worth Asking Before You Enroll
Walking into a screening visit with a list of questions changes the dynamic. Research coordinators expect questions and answering them is part of their job. Here are a few that experienced participants recommend:
What is the time commitment over the full study period? Some trials require weekly visits for the first month, then monthly visits for a year. Knowing the schedule upfront prevents surprises.
Is there a placebo group, and what are the odds of being assigned to it? Placebo-controlled trials are standard in asthma research, but the ratio varies. Some studies use a 1:1 randomization; others assign more participants to the active treatment arm.
What happens to my current medications during the trial? Most asthma trials allow participants to continue their existing controller medications while adding the study drug. Abruptly stopping a prescribed treatment is rarely part of the protocol.
Will the study team share my results with my regular doctor? This is not automatic. Participants can request that lung function results and other findings be forwarded to their primary care provider or pulmonologist.
What happens when the trial ends? Some sponsors offer an open-label extension, where all participants receive the active treatment after the blinded phase concludes. Others do not. Knowing the post-trial plan matters.
Making Sense of the Moment
Asthma research in the United States is in a productive period. The Breztri approval earlier this year shows that the pipeline from clinical trial to pharmacy shelf is functioning. The PASSAGE study's focus on underrepresented populations signals that the field is at least attempting to answer questions about how treatments work across the full spectrum of patients. New biologic candidates like brenipatide and GB-0895 are advancing through the phases.
For someone whose asthma disrupts sleep, limits exercise, or sends them to the emergency department despite following their treatment plan, these developments are not distant. They are happening in research clinics in Tucson, Chicago, New York, Durham, and Denver. The researchers running these studies are actively looking for participants.
The first step is practical: search ClinicalTrials.gov with your location and condition, browse the American Lung Association's trial listings, or call a research center near you. The screening process itself is informative. Even if you do not qualify for a particular study, the lung function testing and clinical evaluation can provide a clearer picture of where your asthma stands.
A conversation with your current doctor about trial participation is also worth having. Some physicians are connected to research networks and can make direct referrals. Others may be cautious about their patients joining studies and will want to review the protocol before giving their blessing. Either way, keeping your care team informed is sensible.
Clinical trials are not the right path for everyone. They require time, willingness to accept uncertainty, and the logistical ability to get to study visits. But for those whose asthma has not responded to available treatments, they represent something that is hard to find elsewhere: the possibility of a different outcome.
研究の知恵